Baxter (BAX) reports Q4 EPS of $0.97, not providing guidance for full-year 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Baxter Reports Fourth-Quarter and Full-Year 2019 Results, Completes Financial Restatement Process
March 17, 2020 7:25 AM EDTFourth-quarter sales of $3.0 billion increased 7% on a reported basis and 9% on an operational basis1 Fourth-quarter GAAP earnings per share (EPS) were a loss of $0.05; adjusted EPS1 totaled $0.97 Full-year sales of $11.4 billion increased 2% on a reported basis and 5% on an operational basis Full-year GAAP EPS were $1.93; adjusted EPS totaled $3.31 With submission of restated financials, company is now current in its SEC reporting obligations
DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE: BAX), a leading global medical products company, today announced its complete... More
